Ductal Carcinoma In Situ: Risk Factors and Impact of Screening

Author： Virnig Beth A. Wang Shi-Yi Shamilyan Tatyana Kane Robert L. Tuttle Todd M.

ISSN： 1052-6773

Source： Journal of the National Cancer Institute Monographs, Vol.2010, Iss.41, 2010-10, pp. : 113-116

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

BackgroundThe National Institutes of Health Office of Medical Applications of Research commissioned a structured literature review on the incidence of ductal carcinoma in situ (DCIS) as a background paper for the State of the Science Conference on Diagnosis and Management of DCIS.MethodsPublished studies were abstracted from MEDLINE and other sources. We include articles published through January 31, 2009; 92 publications were abstracted.ResultsDCIS incidence rose from 1.87 per 100000 in 19731975 to 32.5 per 100000 in 2005. Increases in incidence were greatest in tumors without comedo necrosis. Incidence increased in all ages but more in women older than 50 years. Increased use of mammography explains some but not all of the increased incidence. Risk factors for incident DCIS include older age and positive family history. Whereas tamoxifen prevents both invasive breast cancer and DCIS, raloxifene is associated with decreased invasive breast cancer but not decreased DCIS.ConclusionsScientific questions deserving further investigation include the relationship between mammography use and DCIS incidence and the role of chemoprevention for reducing the incidence of DCIS and invasive breast cancer.